Recombinant plasma protein therapeutics market is driven by various factors such as shift from use of plasma-derived proteins to recombinant therapies, rise in awareness about rare disease management and increased focus on investments in rare diseases.
This report contains market size and forecasts of Recombinant Plasma Protein Therapeutics in global, including the following market information:
- Global Recombinant Plasma Protein Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global Recombinant Plasma Protein Therapeutics Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Recombinant Plasma Protein Therapeutics companies in 2021 (%)
The global Recombinant Plasma Protein Therapeutics market was valued at 8085.3 million in 2021 and is projected to reach US$ 11140 million by 2028, at a CAGR of 4.7% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Recombinant Coagulation Factors Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Recombinant Plasma Protein Therapeutics include CSL Limited, Takeda, Octapharma, Novo Nordisk A/S, Pfizer, Bioverativ Therapeutics, Aptevo Therapeutics and Pharming Group, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Recombinant Plasma Protein Therapeutics manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recombinant Plasma Protein Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Recombinant Plasma Protein Therapeutics Market Segment Percentages, by Type, 2021 (%)
- Recombinant Coagulation Factors
- Human C1 Esterase Inhibitor
Global Recombinant Plasma Protein Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Recombinant Plasma Protein Therapeutics Market Segment Percentages, by Application, 2021 (%)
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
Global Recombinant Plasma Protein Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Recombinant Plasma Protein Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Recombinant Plasma Protein Therapeutics revenues in global market, 2017-2022 (Estimated), ($ millions)
- Key companies Recombinant Plasma Protein Therapeutics revenues share in global market, 2021 (%)
- Key companies Recombinant Plasma Protein Therapeutics sales in global market, 2017-2022 (Estimated), (K Units)
- Key companies Recombinant Plasma Protein Therapeutics sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- CSL Limited
- Takeda
- Octapharma
- Novo Nordisk A/S
- Pfizer
- Bioverativ Therapeutics
- Aptevo Therapeutics
- Pharming Group
